23 Gastric and colorectal cancers remain major causes of cancer related illness and death worldwide. Precision oncology has improved outcomes for some patients, but traditional approaches have often relied on static, single point models. These can struggle to account for spatial differences within tumours and the ongoing clonal evolution that contributes to disease progression and treatment resistance. A new review published in LabMed Discovery proposes a different approach. Researchers outline a spatio temporal integration adaptive closed loop paradigm designed to support more dynamic, responsive care and improve clinical decision making throughout a patient’s treatment journey. In the spatial dimension, the model integrates multi omics data with multimodal imaging to build a comprehensive tumour atlas. This aims to capture the complex architecture of the disease more fully than a single biopsy. The temporal dimension uses longitudinal monitoring through liquid biopsy techniques such as circulating tumour DNA, or ctDNA. Serial testing allows clinicians to track clonal evolution over time and functionally stratify biomarkers according to how they change, rather than relying on a single snapshot. Artificial intelligence forms the third element by integrating these spatial and temporal data streams. AI driven decision support operates across three stages: T1 prediction, T2 adaptation, and T3 interception. At the baseline T1 stage, models help estimate treatment benefit and guide initial therapy selection. During treatment, T2 supports adaptation by assessing response and emerging resistance. In the surveillance phase, T3 focuses on interception by estimating recurrence or minimal residual disease risk and supporting earlier intervention. The review classifies biomarkers into four categories: early screening, prognostic stratification, treatment response prediction, and recurrence monitoring. It stresses that biomarker performance and clinical applicability are highly specific to cancer type and clinical setting. Findings from one gastrointestinal tumour should not simply be extrapolated to another. The authors also examine clinical evidence from the DYNAMIC III trial. In the study, ctDNA guided downstaging of adjuvant therapy reduced exposure to oxaliplatin and associated toxicity. However, the pre specified non inferiority criteria were not met, meaning the clinical utility of the approach requires cautious interpretation. The review identifies several translational barriers that must be overcome, including greater testing standardisation, cost management, robust clinical validation, and improved generalisation capability for AI systems. The authors propose practical strategies to address these barriers and outline future research priorities, including standardised regulation, advances in multimodal AI and digital twins, progress in the clinical translation of spatial multi omics, and the design of adaptive clinical trials. Although substantial practical hurdles remain, the review provides a conceptual roadmap for the next phase of precision care. Carefully designed clinical trials will be essential to assess the real world performance of the integrated approach. If validated, the framework could support more personalised treatment decisions, reduce unnecessary treatment toxicity, improve recurrence detection, and potentially enhance outcomes for patients with gastric and colorectal cancers.